Spain's Highlight Has High Hopes For Immuno-Oncology Agent
Teamed Up With Merck & Co To Overcome PD1 Resistance
Executive Summary
After a decade of research, the Spanish biotech believes its lead candidate BO-112 can turn ‘cold’ tumors ‘hot,' offering the potential to rescue patients who are resistant to current checkpoint inhibitor therapy.